0
Signin
countryflagUS

18889881171

AAPL 173.18 2.2918% MSFT 397.84 0.7343% GOOG 168.46 1.7455% GOOGL 166.62 1.6844% AMZN 184.72 3.1955% NVDA 858.11 3.3357% META 441.84 0.6034% TSLA 180.1 0.0611% TSM 136.23 0.956% LLY 755.91 -2.683% V 267.61 0.1085% AVGO 1238.3 -0.3669% JPM 191.66 -0.1042% UNH 492.97 1.8302% NVO 124.02 -4.0167% WMT 59.71 1.4613% LVMUY 164.94 0.5609% XOM 116.24 0.181% LVMHF 825.49 0.3843% MA 441.1 -0.2194%

Seer Inc

Healthcare US SEER

2.16USD
0.04(1.89%)

Last update at 2024-05-02T20:00:00Z

Day Range

2.042.16
LowHigh

52 Week Range

1.466.18
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -92.96600M -71.16900M -32.77500M -16.03800M -6.30700M
Minority interest - - - - -
Net income -88.69700M -68.63300M -31.16900M -16.04300M -6.30700M
Selling general administrative 58.53M 45.76M 15.36M 4.61M 2.98M
Selling and marketing expenses - - - - -
Gross profit 6.74M 3.19M 0.66M 0.06M -
Reconciled depreciation 3.94M 2.56M 1.61M 0.70M 0.03M
Ebit -97.23500M -71.47300M -33.64900M -16.88300M -6.30700M
Ebitda -92.96600M -71.14700M -32.76600M -15.33200M -6.27600M
Depreciation and amortization 4.27M 0.33M 0.88M 1.55M 0.03M
Non operating income net other 4.27M 0.33M - - -
Operating income -97.23500M -71.47300M -33.64900M -16.88300M -6.75800M
Other operating expenses 111.92M 77.87M 34.30M 16.94M 6.76M
Interest expense 0.33M 0.02M 0.00900M 0.00500M 0.00000M
Tax provision - - - - -
Interest income 4.60M 0.33M 0.88M 0.85M 0.45M
Net interest income 4.60M 0.30M 0.87M 0.84M 0.45M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.26900M -2.53600M -1.60600M 0.00500M 0.45M
Total revenue 14.69M 6.39M 0.66M 0.06M 0.00000M
Total operating expenses 103.98M 74.66M 34.30M 16.94M 6.76M
Cost of revenue 7.94M 3.21M - - -
Total other income expense net 4.27M 0.30M 0.87M 0.84M 0.45M
Discontinued operations - - - - -
Net income from continuing ops -92.96600M -71.16900M -32.77500M -16.03800M -6.30700M
Net income applicable to common shares -92.96600M -71.16900M -32.77500M -16.03800M -6.30700M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 487.93M 539.14M 442.32M 93.24M 33.70M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.10M 3.34M 0.45M 0.46M 0.19M
Total liab 40.94M 36.22M 10.71M 5.56M 3.72M
Total stockholder equity 446.99M 502.92M 431.61M 87.68M 29.98M
Deferred long term liab - - - - -
Other current liab 8.51M 8.39M 0.48M 2.94M 1.07M
Common stock 0.00100M 0.00100M 0.00100M - -
Capital stock 0.00100M 0.00100M 0.00100M 107.95M 35.81M
Retained earnings -219.49600M -126.53000M -55.36100M -22.58600M -6.54800M
Other liab 0.32M 0.34M 2.62M 1.74M 0.03M
Good will - - - - -
Other assets 1.38M 539.14M 0.75M 0.74M 0.12M
Cash 53.21M 232.81M 333.58M 17.48M 30.95M
Cash and equivalents - - - - -
Total current liabilities 12.58M 13.42M 8.09M 3.81M 3.69M
Current deferred revenue 0.13M 0.38M 0.25M 0.17M -
Net debt -23.33400M -209.49000M -333.58500M -17.48500M -30.95300M
Short term debt 1.84M 0.86M 5.25M - -
Short long term debt - - - - -
Short long term debt total 29.87M 23.32M - - -
Other stockholder equity 667.74M 629.98M 486.92M 2.29M 0.74M
Property plant equipment 19.41M 33.23M 8.44M 5.69M 2.36M
Total current assets 434.98M 411.70M 433.13M 86.81M 31.21M
Long term investments 5.16M 93.19M - - -
Net tangible assets 446.99M 502.92M 431.61M -20.27400M -5.83700M
Short term investments 368.03M 167.26M 98.28M 68.53M 0.00000M
Net receivables 7.02M 4.14M 0.26M 0.33M 0.07M
Long term debt - - - - -
Inventory 4.63M 4.14M 0.55M - -
Accounts payable 2.10M 3.79M 2.12M 0.70M 2.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.25100M -0.53600M 0.05M 0.02M -0.03100M
Additional paid in capital - - - - -
Common stock total equity 0.00100M 0.00100M 0.00100M - -
Preferred stock total equity - - - - -
Retained earnings total equity -219.49600M -126.53000M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.38M 1.02M 0.75M 0.74M 0.12M
Deferred long term asset charges - - - - -
Non current assets total 52.95M 127.44M 9.19M 6.43M 2.48M
Capital lease obligations 29.87M 23.32M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -112.62300M -163.95600M -30.02400M -68.25200M -68.25200M
Change to liabilities -1.30200M 3.75M 0.99M 0.39M 0.32M
Total cashflows from investing activities -122.71800M -170.87800M -34.55800M -72.38300M -0.16800M
Net borrowings - - - 0.40M 0.40M
Total cash from financing activities 3.89M 116.63M 371.49M 72.33M 29.95M
Change to operating activities -2.18800M -1.50500M 2.22M 0.82M 0.70M
Net income -92.96600M -71.16900M -32.77500M -16.03800M -6.30700M
Change in cash -179.60500M -100.59100M 316.10M -13.12500M 25.13M
Begin period cash flow 233.34M 333.93M 17.83M 30.95M 5.83M
End period cash flow 53.73M 233.34M 333.93M 17.83M 30.95M
Total cash from operating activities -60.78000M -46.34700M -20.82800M -13.07300M -4.65100M
Issuance of capital stock 0.00000M 102.96M 370.23M 71.93M 29.95M
Depreciation 3.94M 2.56M 1.61M 0.70M 0.03M
Other cashflows from investing activities 0.17M - - - -
Dividends paid - - - - -
Change to inventory -1.59000M -3.59400M -0.55100M -0.55100M -0.55100M
Change to account receivables -1.82000M -2.49500M 2.04M -0.25700M -0.06900M
Sale purchase of stock -0.02000M -0.03500M -0.01300M -0.00600M 0.00000M
Other cashflows from financing activities 0.78M 13.71M 56.16M 72.34M 29.89M
Change to netincome 34.51M 25.93M 7.62M 1.30M 0.67M
Capital expenditures 10.27M 6.92M 4.53M 4.13M 0.17M
Change receivables -2.87400M -3.88200M - - -
Cash flows other operating 0.33M -1.12900M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -179.60500M -100.59100M - - -
Change in working capital -7.39400M -5.86500M 2.72M 0.96M 0.95M
Stock based compensation 33.67M 25.93M 7.35M 1.56M 0.67M
Other non cash items 1.97M 1.00M 0.01000M 0.00500M -
Free cash flow -71.04500M -53.26900M -25.36200M -17.20400M -4.81900M

Fundamentals

  • Previous Close 2.12
  • Market Cap121.26M
  • Volume216133
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-101.07900M
  • Revenue TTM16.83M
  • Revenue Per Share TTM0.27
  • Gross Profit TTM 7.09M
  • Diluted EPS TTM-1.43

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SEER
Seer Inc		 0.04 1.89% 2.16 - - 6.54 0.26 0.11 2.03
NVO
Novo Nordisk A/S		 -5.19 4.02% 124.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.236 1.77% 124.22 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.98 0.49% 400.16 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 1.91 2.14% 91.05 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Oregon Health & Science University; The Broad Institute of MIT and Harvard; Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Seer Inc

3800 Bridge Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Dr. Omid C. Farokhzad M.D., Ph.D. Founder, Pres, CEO & Chair of the Board of Directors 1969
Mr. David R. Horn Exec. VP, Treasurer & CFO 1968
Ms. Elona Kogan Esq., J.D. Gen. Counsel & Sec. 1969
Mr. Joe Laws Chief Technology Officer and Co-Founder NA
Kenny Ross Chief Operations & Product Officer NA
Ms. Karen Possemato Chief Marketing Officer NA
Ms. Marissa Dixon Chief People Officer NA
Dr. Serafim Batzoglou Ph.D. Chief Data Officer NA
Mr. Martin Goldberg Ph.D. Sr. VP of Devel. NA
Mr. Scott D. Thomas Chief Commercial Officer 1973

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).